Harbour Antibodies Licenses H2L2 Mice to Pfizer Business Wire ROTTERDAM, the Netherlands & CAMBRIDGE, Mass. -- July 24, 2013 Harbour Antibodies, the creator of transgenic mice to aid in the development of new human therapeutic antibodies, announced today that it has licensed its H2L2 mice, which can generate human monoclonal antibodies, to Pfizer Inc. Harbour Antibodies’ transgenic H2L2 mice enable biotechs, pharmaceutical companies and academic research labs to speed new drug development by generating human antibodies using traditional hybridoma technology. Under the licensing agreement, Pfizer will have the option to use the mice in as many projects as they wish without disclosing the nature of the projects to Harbour. This licensing deal marks the third partnership for Harbour Antibodies. Previous deals have been announced involving the H2L2 mice with Eli Lilly and Company and ChemPartner Co. About Harbour Antibodies. Harbour Antibodies is enabling the development of new therapeutic human monoclonal antibodies through the creation of two lines of transgenic mice. These are the H2L2 mice, which generate full IgG and the HCAb mice, which generate heavy chain only human antibodies. Both lines are currently available for licensing. For more information, please visitwww.harbourantibodies.com. Contact: Harbour Antibodies BJ Bormann, PhD, +1 617-203-2182 Ext 1 CEO firstname.lastname@example.org
Harbour Antibodies Licenses H2L2 Mice to Pfizer
Press spacebar to pause and continue. Press esc to stop.